GB201713660D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB201713660D0
GB201713660D0 GBGB1713660.7A GB201713660A GB201713660D0 GB 201713660 D0 GB201713660 D0 GB 201713660D0 GB 201713660 A GB201713660 A GB 201713660A GB 201713660 D0 GB201713660 D0 GB 201713660D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1713660.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Priority to GBGB1713660.7A priority Critical patent/GB201713660D0/en
Publication of GB201713660D0 publication Critical patent/GB201713660D0/en
Priority to CA3071772A priority patent/CA3071772A1/en
Priority to CN201880052445.0A priority patent/CN111032018A/zh
Priority to TW107128107A priority patent/TW201919600A/zh
Priority to PCT/GB2018/052292 priority patent/WO2019030540A1/en
Priority to EP18758700.1A priority patent/EP3664780A1/en
Priority to SG11202001179YA priority patent/SG11202001179YA/en
Priority to AU2018315034A priority patent/AU2018315034A1/en
Priority to MX2020001356A priority patent/MX2020001356A/es
Priority to US16/637,953 priority patent/US20200261383A1/en
Priority to UAA202001624A priority patent/UA125537C2/uk
Priority to MA049837A priority patent/MA49837A/fr
Priority to RU2020109955A priority patent/RU2020109955A/ru
Priority to JP2020507672A priority patent/JP2020530475A/ja
Priority to KR1020207007099A priority patent/KR20200038987A/ko
Priority to BR112020002325-6A priority patent/BR112020002325A2/pt
Priority to PH12020500246A priority patent/PH12020500246A1/en
Priority to IL272428A priority patent/IL272428A/en
Priority to CL2020000356A priority patent/CL2020000356A1/es
Priority to CONC2020/0002287A priority patent/CO2020002287A2/es
Priority to ECSENADI202017939A priority patent/ECSP20017939A/es
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GBGB1713660.7A 2017-08-11 2017-08-25 Pharmaceutical compositions Ceased GB201713660D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1713660.7A GB201713660D0 (en) 2017-08-25 2017-08-25 Pharmaceutical compositions
BR112020002325-6A BR112020002325A2 (pt) 2017-08-11 2018-08-13 composições farmacêuticas
UAA202001624A UA125537C2 (uk) 2017-08-11 2018-08-13 Фармацевтична композиція інгібітора плазмового калікреїну, способи її отримання (варіанти) і застосування
RU2020109955A RU2020109955A (ru) 2017-08-11 2018-08-13 Фармацевтические композиции
TW107128107A TW201919600A (zh) 2017-08-11 2018-08-13 醫藥組合物
PCT/GB2018/052292 WO2019030540A1 (en) 2017-08-11 2018-08-13 PHARMACEUTICAL COMPOSITIONS
EP18758700.1A EP3664780A1 (en) 2017-08-11 2018-08-13 Pharmaceutical compositions
SG11202001179YA SG11202001179YA (en) 2017-08-11 2018-08-13 Pharmaceutical compositions
AU2018315034A AU2018315034A1 (en) 2017-08-11 2018-08-13 Pharmaceutical compositions
MX2020001356A MX2020001356A (es) 2017-08-11 2018-08-13 Composiciones farmaceuticas.
US16/637,953 US20200261383A1 (en) 2017-08-11 2018-08-13 Pharmaceutical compositions
CA3071772A CA3071772A1 (en) 2017-08-11 2018-08-13 Pharmaceutical compositions
MA049837A MA49837A (fr) 2017-08-11 2018-08-13 Compositions pharmaceutiques
CN201880052445.0A CN111032018A (zh) 2017-08-11 2018-08-13 药物组合物
JP2020507672A JP2020530475A (ja) 2017-08-11 2018-08-13 医薬組成物
KR1020207007099A KR20200038987A (ko) 2017-08-11 2018-08-13 약제학적 조성물
IL272428A IL272428A (en) 2017-08-11 2020-02-03 pharmaceutical preparations
PH12020500246A PH12020500246A1 (en) 2017-08-11 2020-02-03 Pharmaceutical compositions
CL2020000356A CL2020000356A1 (es) 2017-08-11 2020-02-11 Composiciones farmacéuticas.
CONC2020/0002287A CO2020002287A2 (es) 2017-08-11 2020-02-28 Composiciones farmacéuticas
ECSENADI202017939A ECSP20017939A (es) 2017-08-11 2020-03-11 Composiciones farmacéuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713660.7A GB201713660D0 (en) 2017-08-25 2017-08-25 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB201713660D0 true GB201713660D0 (en) 2017-10-11

Family

ID=60037096

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1713660.7A Ceased GB201713660D0 (en) 2017-08-11 2017-08-25 Pharmaceutical compositions

Country Status (13)

Country Link
US (1) US20200261383A1 (enExample)
EP (1) EP3664780A1 (enExample)
JP (1) JP2020530475A (enExample)
KR (1) KR20200038987A (enExample)
CN (1) CN111032018A (enExample)
AU (1) AU2018315034A1 (enExample)
BR (1) BR112020002325A2 (enExample)
CA (1) CA3071772A1 (enExample)
GB (1) GB201713660D0 (enExample)
MA (1) MA49837A (enExample)
SG (1) SG11202001179YA (enExample)
TW (1) TW201919600A (enExample)
WO (1) WO2019030540A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
GB2591730A (en) * 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
AU2013265255B2 (en) * 2012-05-25 2018-03-29 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
GB2510407A (en) * 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration

Also Published As

Publication number Publication date
BR112020002325A2 (pt) 2020-09-01
CN111032018A (zh) 2020-04-17
JP2020530475A (ja) 2020-10-22
KR20200038987A (ko) 2020-04-14
TW201919600A (zh) 2019-06-01
EP3664780A1 (en) 2020-06-17
MA49837A (fr) 2020-06-17
WO2019030540A1 (en) 2019-02-14
CA3071772A1 (en) 2019-02-14
AU2018315034A1 (en) 2020-02-27
US20200261383A1 (en) 2020-08-20
SG11202001179YA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
IL271657A (en) medical preparation
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986B1 (en) pharmaceutical preparation
GB201608323D0 (en) Pharmaceutical compositions
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
GB201712159D0 (en) Pharmaceutical composition
HUE068810T2 (hu) Gyógyászati készítmény
GB201705303D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
GB201705304D0 (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
PL3646867T3 (pl) Kompozycja farmaceutyczna
GB201705306D0 (en) Pharmaceutical compositions
IL255510A (en) Pharmaceutical compositions
ZA202000014B (en) Pharmaceutical compositions
IL263999A (en) Pharmaceutical compositions
IL272044A (en) Pharmacy preparations
ZA201705782B (en) Pharmaceutical compositions
IL272428A (en) pharmaceutical preparations
GB201715404D0 (en) Pharmaceutical compositions
GB201710114D0 (en) Pharmaceutical compositions
GB201706816D0 (en) Pharmaceutical compositions
GB201705301D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)